Keytruda® (pembrolizumab) – Expanded indication
October 30, 2018 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with carboplatin and either paclitaxel or Abraxane® (nab-paclitaxel), as first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).
Top